Annual CFF
$26.69 M
+$25.66 M+2481.33%
December 31, 2024
Summary
- As of March 13, 2025, ITRM annual cash flow from financing activities is $26.69 million, with the most recent change of +$25.66 million (+2481.33%) on December 31, 2024.
- During the last 3 years, ITRM annual CFF has fallen by -$56.44 million (-67.89%).
- ITRM annual CFF is now -78.16% below its all-time high of $122.20 million, reached on December 31, 2018.
Performance
ITRM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$13.88 M
+$8.45 M+155.56%
December 1, 2024
Summary
- As of March 13, 2025, ITRM quarterly cash flow from financing activities is $13.88 million, with the most recent change of +$8.45 million (+155.56%) on December 1, 2024.
- Over the past year, ITRM quarterly CFF has increased by +$8.45 million (+155.56%).
- ITRM quarterly CFF is now -84.35% below its all-time high of $88.66 million, reached on June 30, 2018.
Performance
ITRM Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$26.69 M
+$13.29 M+99.14%
December 1, 2024
Summary
- As of March 13, 2025, ITRM TTM cash flow from financing activities is $26.69 million, with the most recent change of +$13.29 million (+99.14%) on December 1, 2024.
- Over the past year, ITRM TTM CFF has increased by +$13.29 million (+99.14%).
- ITRM TTM CFF is now -78.16% below its all-time high of $122.20 million, reached on December 31, 2018.
Performance
ITRM TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ITRM Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2481.3% | +155.6% | +99.1% |
| 3 y3 years | -67.9% | +155.6% | +99.1% |
| 5 y5 years | +1193.8% | +155.6% | +99.1% |
ITRM Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -67.9% | +1568.2% | at high | +716.5% | -67.9% | +537.1% |
| 5 y | 5-year | -67.9% | +1568.2% | -84.0% | +716.5% | -74.7% | +537.1% |
| alltime | all time | -78.2% | +1568.2% | -84.3% | +716.5% | -78.2% | +537.1% |
Iterum Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $26.69 M(+2481.3%) | - | - |
| Dec 2024 | - | $13.88 M(+155.6%) | $26.69 M(+99.1%) |
| Sep 2024 | - | $5.43 M(+3151.5%) | $13.40 M(+67.9%) |
| Jun 2024 | - | $167.00 K(-97.7%) | $7.98 M(-0.4%) |
| Mar 2024 | - | $7.22 M(+1125.3%) | $8.02 M(+675.2%) |
| Dec 2023 | $1.03 M(-156.9%) | $589.00 K(+5790.0%) | $1.03 M(+17.8%) |
| Sep 2023 | - | $10.00 K(-95.0%) | $878.00 K(+1.2%) |
| Jun 2023 | - | $200.00 K(-14.9%) | $868.00 K(+29.9%) |
| Mar 2023 | - | $235.00 K(-45.7%) | $668.00 K(-136.7%) |
| Dec 2022 | -$1.82 M(-102.2%) | $433.00 K(>+9900.0%) | -$1.82 M(-53.1%) |
| Sep 2022 | - | $0.00(0.0%) | -$3.88 M(-29.6%) |
| Jun 2022 | - | $0.00(-100.0%) | -$5.51 M(-9.7%) |
| Mar 2022 | - | -$2.25 M(+38.2%) | -$6.11 M(-107.3%) |
| Dec 2021 | $83.13 M(+28.9%) | -$1.63 M(-0.3%) | $83.13 M(-16.8%) |
| Sep 2021 | - | -$1.63 M(+176.0%) | $99.88 M(-2.3%) |
| Jun 2021 | - | -$592.00 K(-100.7%) | $102.28 M(-3.1%) |
| Mar 2021 | - | $86.98 M(+475.0%) | $105.59 M(+63.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $64.47 M(+3025.3%) | $15.13 M(+1872.2%) | $64.47 M(+33.4%) |
| Sep 2020 | - | $767.00 K(-71.7%) | $48.31 M(-4.5%) |
| Jun 2020 | - | $2.71 M(-94.1%) | $50.59 M(+5.6%) |
| Mar 2020 | - | $45.87 M(-4536.3%) | $47.88 M(+2221.1%) |
| Dec 2019 | $2.06 M(-98.3%) | -$1.03 M(-134.0%) | $2.06 M(-53.8%) |
| Sep 2019 | - | $3.04 M(>+9900.0%) | $4.47 M(+212.7%) |
| Jun 2019 | - | $10.00 K(-79.6%) | $1.43 M(-98.4%) |
| Mar 2019 | - | $49.00 K(-96.4%) | $90.08 M(-26.3%) |
| Dec 2018 | $122.20 M(+166.4%) | $1.37 M(>+9900.0%) | $122.20 M(+1.1%) |
| Sep 2018 | - | $0.00(-100.0%) | $120.83 M(0.0%) |
| Jun 2018 | - | $88.66 M(+175.5%) | $120.83 M(+54.8%) |
| Mar 2018 | - | $32.18 M(>+9900.0%) | $78.04 M(+70.2%) |
| Dec 2017 | $45.87 M(+120.0%) | $0.00(0.0%) | $45.87 M(0.0%) |
| Sep 2017 | - | $0.00(-100.0%) | $45.87 M(0.0%) |
| Jun 2017 | - | $45.87 M(>+9900.0%) | $45.87 M(>+9900.0%) |
| Mar 2017 | - | $0.00 | $0.00 |
| Dec 2016 | $20.85 M | - | - |
FAQ
- What is Iterum Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Iterum Therapeutics?
- What is Iterum Therapeutics annual CFF year-on-year change?
- What is Iterum Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Iterum Therapeutics?
- What is Iterum Therapeutics quarterly CFF year-on-year change?
- What is Iterum Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Iterum Therapeutics?
- What is Iterum Therapeutics TTM CFF year-on-year change?
What is Iterum Therapeutics annual cash flow from financing activities?
The current annual CFF of ITRM is $26.69 M
What is the all time high annual CFF for Iterum Therapeutics?
Iterum Therapeutics all-time high annual cash flow from financing activities is $122.20 M
What is Iterum Therapeutics annual CFF year-on-year change?
Over the past year, ITRM annual cash flow from financing activities has changed by +$25.66 M (+2481.33%)
What is Iterum Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ITRM is $13.88 M
What is the all time high quarterly CFF for Iterum Therapeutics?
Iterum Therapeutics all-time high quarterly cash flow from financing activities is $88.66 M
What is Iterum Therapeutics quarterly CFF year-on-year change?
Over the past year, ITRM quarterly cash flow from financing activities has changed by +$8.45 M (+155.56%)
What is Iterum Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ITRM is $26.69 M
What is the all time high TTM CFF for Iterum Therapeutics?
Iterum Therapeutics all-time high TTM cash flow from financing activities is $122.20 M
What is Iterum Therapeutics TTM CFF year-on-year change?
Over the past year, ITRM TTM cash flow from financing activities has changed by +$13.29 M (+99.14%)